Inventor · disambiguated record
Kendall M. Mohler
Also filed as: MOHLER KENDALL · MOHLER KENDALL M · MOHLER KENDALL MARK
9 granted patents·19 pending applications·129 citations·filing 2001–2024
89Inventor score
Files withIMMUNEX CORP11NEUVOGEN INC10JUNO THERAPEUTICS INC4BAKER HUGHES HOLDINGS LLC1EMERGENT PRODUCT DEV SEATTLE1
Top patents by PatentIndex Score
28 records- 0194US10738278B2Engineered cells for adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2015·Granted Aug 11, 2020·8 cites·21 claims
- 0294US6793919B2Methods for treating rheumatoid arthritis using IL-17 antagonistsIMMUNEX CORP·Filed 2001·Granted Sep 21, 2004·65 cites·9 claims
- 0389US10786533B2Engineered cells for adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2016·Granted Sep 29, 2020·4 cites·24 claims
- 0488US11369668B1Tumor cell vaccinesNEUVOGEN INC·Filed 2021·Granted Jun 28, 2022·4 cites·16 claims
- 0587US6652854B2Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30LIMMUNEX CORP·Filed 2001·Granted Nov 25, 2003·27 cites·24 claims
- 0685US7273609B2Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30LIMMUNEX CORP·Filed 2006·Granted Sep 25, 2007·8 cites·13 claims
- 0784US11684659B2Tumor cell vaccinesNEUVOGEN INC·Filed 2022·Granted Jun 27, 2023·1 cites·4 claims
- 0880US7122183B2Methods for treating autoimmune and chronic inflammatory conditions using antagonists of CD30 or CD30LIMMUNEX CORP·Filed 2003·Granted Oct 17, 2006·12 cites·23 claims
- 0978US2025302931A1Colorectal cancer tumor cell vaccinesNEUVOGEN INC·Filed 2024·Application pending·0 cites
- 1078US2025332235A1Breast cancer tumor cell vaccinesNEUVOGEN INC·Filed 2024·Application pending·0 cites
- 1174US2009297517A1Methods for treating il-18 mediated disordersIMMUNEX CORP·Filed 2009·Application pending·0 cites
- 1272US2023414733A1Tumor cell vaccinesNEUVOGEN INC·Filed 2023·Application pending·0 cites
- 1366US2022133869A1Breast cancer tumor cell vaccinesNEUVOGEN INC·Filed 2021·Application pending·0 cites
- 1466US2022133868A1Tumor cell vaccinesNEUVOGEN INC·Filed 2021·Application pending·0 cites
- 1566US2022152169A1Colorectal cancer tumor cell vaccinesNEUVOGEN INC·Filed 2021·Application pending·0 cites
- 1666US2010071079A1Methods for treating autoimmune and chronic inflammatory conditions using antagonists of cd30 or cd30lIMMUNEX CORP·Filed 2009·Application pending·0 cites
- 1765US2021252122A1Tumor cell vaccinesNEUVOGEN INC·Filed 2021·Application pending·0 cites
- 1865US2009274703A1Methods of treating inflammation using IL-17 antagonistsIMMUNEX CORP·Filed 2009·Application pending·0 cites
- 1963US12191744B2Continuously welded capillary tubing over insulated conductor for ESP applicationsBAKER HUGHES HOLDINGS LLC·Filed 2021·Granted Jan 7, 2025·0 cites·18 claims
- 2063US2009130122A1Methods for treating rheumatoid arthritis using IL-17 antagonistsIMMUNEX CORP·Filed 2008·Application pending·0 cites
- 2161US2021205428A1Tumor cell vaccinesNEUVOGEN INC·Filed 2020·Application pending·0 cites
- 2260US2020384031A1Engineered cells for adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2360US2020318070A1Engineered cells for adoptive cell therapyJUNO THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2460US2008213259A1Methods for Treating Autoimmune and Chronic Inflammatory Conditions Using Antagonists of CD30 or CD30LIMMUNEX CORP·Filed 2007·Application pending·0 cites
- 2558US2005013814A1Methods for treating rheumatoid arthritis using IL-17 antagonistsIMMUNEX CORP·Filed 2004·Application pending·0 cites
- 2657US2002098185A1Methods for treating IL-18 mediated disordersFiled 2002·Application pending·0 cites
- 2753US2010278840A1Methods for treating rheumatoid arthritis using il-17 antagonistsIMMUNEX CORP·Filed 2010·Application pending·0 cites
- 2847US2011152173A1TNF-a ANTAGONIST MULTI-TARGET BINDING PROTEINSEMERGENT PRODUCT DEV SEATTLE·Filed 2009·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Kendall M. Mohler files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →